Ebola virus vaccine - Profectus Biosciences

Drug Profile

Ebola virus vaccine - Profectus Biosciences

Alternative Names: Ebola Zaire Vaccine - Profectus Biosciences; Monovalent vesicular stomatitis virus vectored Ebola virus vaccine - Profectus Biosciences; rVSVN4CT1 EBOVGP1; VesiculoVax™ Zaire-Ebola virus - Profectus Biosciences; VesiculoVax™-vectored Ebola virus vaccine - Profectus Biosciences

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Profectus Biosciences
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 19 Jan 2016 Phase-I clinical trials in Ebola virus infections (Prevention) in USA (IM)
  • 23 Sep 2011 Preclinical trials in Ebola virus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top